{"id":16,"date":"2025-03-28T12:12:04","date_gmt":"2025-03-28T11:12:04","guid":{"rendered":"https:\/\/archivio.smc-media.eu\/reposi2015\/?page_id=16"},"modified":"2025-03-28T12:37:06","modified_gmt":"2025-03-28T11:37:06","slug":"home","status":"publish","type":"page","link":"https:\/\/archivio.smc-media.eu\/reposi2015\/","title":{"rendered":"Home"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;section&#8221; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_row admin_label=&#8221;row&#8221; _builder_version=&#8221;4.16&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_code admin_label=&#8221;h1&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h1>About REPOSI 2015<\/h1>\n<p>[\/et_pb_code][et_pb_code _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; admin_label=&#8221;.giustificato&#8221; module_class=&#8221;giustificato&#8221; sticky_enabled=&#8221;0&#8243;]<pee>The huge demographic changes that are <!-- [et_pb_line_break_holder] -->occurring in populations of high- and middle-income countries in Europe <!-- [et_pb_line_break_holder] -->are leading to a dramatic increase in the number of the oldest citizens <!-- [et_pb_line_break_holder] -->(80+ years), who in the next 20-30 years are expected to represent 10% <!-- [et_pb_line_break_holder] -->of the total continent population. This age group is likely to be <!-- [et_pb_line_break_holder] -->affected by multiple chronic diseases, which will lead almost inevitably<!-- [et_pb_line_break_holder] --> to the concomitant prescription of multiple drugs and thus to a high <!-- [et_pb_line_break_holder] -->risk of their incompatibility that may have severe adverse effects.<\/pee><!-- [et_pb_line_break_holder] --><pee>For instance, one of the main issues and<!-- [et_pb_line_break_holder] --> a critical problem in the field of multimorbidity and polypharmacy is <!-- [et_pb_line_break_holder] -->the use of anticoagulants in the frame of the treatment of atrial <!-- [et_pb_line_break_holder] -->fibrillation and venous thromboembolism, because many of the other drugs<!-- [et_pb_line_break_holder] --> that the elderly take may interfere with the hemostasis and thus <!-- [et_pb_line_break_holder] -->increase the risk of bleeding.<\/pee><!-- [et_pb_line_break_holder] --><pee>The purpose of this Seminar is to gather<!-- [et_pb_line_break_holder] --> a number of European experts in order to evaluate the methods and <!-- [et_pb_line_break_holder] -->procedures they have developed in their clinical practice and research <!-- [et_pb_line_break_holder] -->projects to improve multiple drug prescription and to avoid the related <!-- [et_pb_line_break_holder] -->mishaps.<\/pee><!-- [et_pb_line_break_holder] --><pee>The objective is not only to decrease <!-- [et_pb_line_break_holder] -->the risk of adverse effects of polypharmacy but also to improve quality <!-- [et_pb_line_break_holder] -->of life and symptom relief in the elderly, i.e. the most important <!-- [et_pb_line_break_holder] -->clinical outcomes in people with limited life expectancy.<\/pee><!-- [et_pb_line_break_holder] --><pee>The Seminar scientific program will aim <!-- [et_pb_line_break_holder] -->to define and categorise appropriate prescribing, critically review the <!-- [et_pb_line_break_holder] -->instruments currently available to tailor polypharmacy, to control its <!-- [et_pb_line_break_holder] -->effects and to discuss the effects of available optimisation strategies <!-- [et_pb_line_break_holder] -->in the elderly.<\/pee><!-- [et_pb_line_break_holder] --><pee>Finally, the Seminar has the goal to <!-- [et_pb_line_break_holder] -->suggest directions for future research and practice in the field of <!-- [et_pb_line_break_holder] -->multimorbidity and related polypharmacy.<\/pee>[\/et_pb_code][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-16","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/archivio.smc-media.eu\/reposi2015\/wp-json\/wp\/v2\/pages\/16","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/archivio.smc-media.eu\/reposi2015\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/archivio.smc-media.eu\/reposi2015\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/archivio.smc-media.eu\/reposi2015\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/archivio.smc-media.eu\/reposi2015\/wp-json\/wp\/v2\/comments?post=16"}],"version-history":[{"count":4,"href":"https:\/\/archivio.smc-media.eu\/reposi2015\/wp-json\/wp\/v2\/pages\/16\/revisions"}],"predecessor-version":[{"id":41,"href":"https:\/\/archivio.smc-media.eu\/reposi2015\/wp-json\/wp\/v2\/pages\/16\/revisions\/41"}],"wp:attachment":[{"href":"https:\/\/archivio.smc-media.eu\/reposi2015\/wp-json\/wp\/v2\/media?parent=16"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}